Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05478174 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia

A Phase 3 study, sponsored by Haisco-USA Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
400
Enrollment target

NCT05478174: Completed Phase 3 study, sponsored by Haisco-USA Pharmaceuticals.

NCT05478174 is a Phase 3 study that has completed, run by Haisco-USA Pharmaceuticals. The registered enrollment target is 400 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05478174, a Phase 3 study, has completed, sponsored by Haisco-USA Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
400 participants
Enrollment target

Study Summary

To demonstrate HSK3486 0.4/0.2 mg/kg (0.4 mg/kg intravenous \[IV\] slow injection over 30 \[±5\] seconds for the first dose, an additional 0.2 mg/kg if needed) is non-inferior to propofol 2.0/1.0 mg/kg (2.0 mg/kg IV slow injection over 30 \[±5\] seconds for first dose, an additional 1.0 mg/kg if needed) in success of induction of general anesthesia in adults undergoing elective surgery.

Primary Outcome

1. Induction success (MOAA/S ≤1) after administration of the study drug, and 2. One or less top-up doses required without using any rescue drugs.

Interventions

  • DRUG Propofol
  • DRUG HSK3486

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2022-07-26
Est. Completion 2023-11-14
Phase Phase 3
Haisco-USA Pharmaceuticals

5 total trials

What the finished NCT05478174 record still lists

NCT05478174 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower).

The record links to 0 conditions, and to 2 interventions - of which Propofol is the first listed.

NCT05478174 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05478174 about?

NCT05478174 is a clinical study titled "Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia". To demonstrate HSK3486 0.4/0.2 mg/kg (0.4 mg/kg intravenous \[IV\] slow injection over 30 \[±5\] seconds for the first dose, an additional 0.2 mg/kg if needed) is non-inferior to propofol 2.0/1.0 mg/kg (2.0 mg/kg IV slow injection over 30 \[±5\] seconds for first dose, an additional 1.0 mg/kg if nee...

What is the current status of trial NCT05478174?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2022-07-26. Estimated completion is 2023-11-14.

What interventions are being tested in trial NCT05478174?

The interventions under investigation include: Propofol (DRUG), HSK3486 (DRUG).

Who is sponsoring clinical trial NCT05478174?

This trial is sponsored by Haisco-USA Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05478174's enrollment target sits among peer trials

400 922nd of 2000 higher than 1,039 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05478174, the US trial registry maintained by the National Library of Medicine. NCT05478174 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.